A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)

被引：0

作者：

Carducci, M. ^{[1
]}

Armstrong, A. ^{[2
,3
]}

Pili, R. ^{[4
]}

Ng, S. ^{[5
]}

Huddart, R. ^{[6
]}

Agarwal, N. ^{[7
]}

Khvorostenko, D. ^{[8
]}

Lyulko, O. ^{[9
]}

Brize, A. ^{[10
]}

Vogelzang, N. J. ^{[11
]}

Delva, R. ^{[12
]}

Harza, M. ^{[13
]}

Thanos, A. ^{[14
]}

James, N. ^{[15
]}

Werbrouck, P. ^{[16
]}

Boegemann, M. ^{[17
]}

Hutson, T. ^{[18
]}

Milecki, P. ^{[19
]}

Nederman, T. ^{[20
]}

Sternberg, C. ^{[21
]}

机构：

[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[2] Duke Canc Inst, Div Med Oncol, Durham, NC USA

[3] Duke Canc Inst, Div Urol, Durham, NC USA

[4] Indiana Univ Sch Med, Div Hematol Oncol, Dept Med, Indianapolis, IN 46202 USA

[5] St John God Hosp, Ivy Suite Canc Ctr, Subiaco, WA, Australia

[6] Royal Marsden Hosp, Clin Oncol, Sutton, Surrey, England

[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[8] Leningrad Reg Oncol Dispensary, St Petersburg, Russia

[9] Municipal Inst Zaporizhzhia Reg Clin Hosp, Dept Urol, Zaporizhzhya, Ukraine

[10] Riga Eastern Clin Univ Hosp, Latvian Oncol Ctr, Riga, Latvia

[11] US Oncol & Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA

[12] Ctr Reg Lutte Canc Paul Papin, Serv Oncol Med, Angers, France

[13] Fundeni Clin Inst, Dept Urol, Bucharest, Romania

[14] Hosp Athens, Urol Clin, Agios Savas Anticanc Oncol, Athens, Greece

[15] Univ Warwick, Canc Res Unit, Warwick, England

[16] AZ Groeninge, Dept Urol, Kortrijk, Belgium

[17] Univ Klinikum Munster, Klin & Polikklin Urol, Munster, Germany

[18] Texas Oncol PA, Collins Bldg, Dallas, TX USA

[19] Wielkopolskie Ctr Onkol, Dept Radiotherapy, Poznan, Poland

[20] Act Biotech AB, Clin Dev, Lund, Sweden

[21] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31934-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4BA

引用

页码：S713 / S714

页数：2

共 50 条

[41] Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
Attard, G.
Gurney, H.
Loriot, Y.
Borre, M.
Andresen, C.
Wu, K.
Taylor, C.
Amelsberg, A.
Taplin, M. E.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S487 - S487
[42] Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
Araujo, John C.
Trudel, Geralyn C.
Saad, Fred
Armstrong, Andrew J.
Yu, Evan Y.
Bellmunt, Joaquim
Wilding, George
McCaffrey, John
Serrano, Sergio V.
Matveev, Vsevolod B.
Efstathiou, Eleni
Oudard, Stephane
Morris, Michael J.
Sizer, Bruce
Goebell, Peter J.
Heidenreich, Axel
de Bono, Johann S.
Begbie, Stephen
Hong, Jun H.
Richardet, Eduardo
Gallardo, Enrique
Paliwal, Prashni
Durham, Susan
Cheng, Shinta
Logothetis, Christopher J.
LANCET ONCOLOGY, 2013, 14 (13): : 1307 - 1316
[43] Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy
Saadipoor, Afshin
Razzaghdoust, Abolfazl
Simforoosh, Nasser
Mahdavi, Arash
Bakhshandeh, Mohsen
Moghadam, Maryam
Abdollahi, Hamid
Mofid, Bahram
PHYTOTHERAPY RESEARCH, 2019, 33 (02) : 370 - 378
[44] Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer
Kantoff, Philip W.
Gulley, James L.
Pico-Navarro, Cesar
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) : 124 - +
[45] PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND STUDY OF INCOBOTULINUMTOXINA FOR SIALORRHEA
Jost, W.
Friedman, A.
Michel, O.
Oehlwein, C.
Slawek, J.
Bogucki, A.
Ochudlo, S.
Banach, M.
Pagan, F.
Flatau-Baque, B.
Csikos, J.
Cairney, C. J.
Blitzer, A.
PARKINSONISM & RELATED DISORDERS, 2023, 113 : 40 - 40
[46] CETACAINE EFFICACY - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY
LACHTER, J
JACOBS, R
LAVY, A
SUISSA, A
WEISLER, A
EIDELMAN, S
GASTROENTEROLOGY, 1988, 94 (05) : A245 - A245
[47] Efficacy and safety of prucalopride in men with chronic constipation: a phase 3, randomized, double-blind, placebo-controlled trial
Yiannakou, Yan
Bouchoucha, Michel
Schiefke, Ingolf
Piessevaux, Hubert
Filip, Rafal
Stephenson, David
Green, Alexandra
Levine, Amy
GASTROENTEROLOGY, 2014, 146 (05) : S160 - S160
[48] Phase III Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC): A randomized, double-blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with metastatic castration-resistant Prostate Cancer (CheckMate-7DX) - AUO Study AP 118/21
Rexer, Heidrun
Boegemann, Martin
Hammerer, Peter
AKTUELLE UROLOGIE, 2022, 53 (03) : 226 - 228
[49] Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
Clarke, Noel
Wiechno, Pawel
Alekseev, Boris
Sala, Nuria
Jones, Robert
Kocak, Ivo
Chiuri, Vincenzo Emanuele
Jassem, Jacek
Flechon, Aude
Redfern, Charles
Goessl, Carsten
Burgents, Joseph
Kozarski, Robert
Hodgson, Darren
Learoyd, Maria
Saad, Fred
LANCET ONCOLOGY, 2018, 19 (07): : 975 - 986
[50] CYCLONE 3: A Phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
Piulats, J. M.
Smith, M.
Matsubara, N.
Zhang, T.
Agarwal, N.
Mckay, R. R.
Johnston, E.
Sherwood, S.
Schaverien, C.
Fasnacht, N.
Lithio, A.
Nacerddine, K.
Todenhoefer, T.
EUROPEAN UROLOGY, 2023, 83 : S757 - S757

← 1 2 3 4 5 →